RANZIN 150 Price

Overview

Welcome to Dwaey, specifically on RANZIN 150 Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Ranitidine (as HCl).
RANZIN 150 is available in the market in concentration 150mg/Tablet and in the form of Tablets/Film-coated.

SHAPHACO PHARMACEUTICAL INDUSTRIES is the producer of RANZIN 150 and it is imported from YEMEN, The most popular alternatives of RANZIN 150 are listed downward .

Mode Of Action

Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.

Indication

• Dyspepsia
• H. pylori infection
• Benign gastric and duodenal ulceration
• GERD
• Acid aspiration during general anesth
• Prophylaxis during NSAID treatment
• Stress ulceration of upper GI
• Zollinger-Ellison syndrome

Precaution

Possibility of malignancy should be excluded prior to therapy as the drug may mask symptoms and delay diagnosis of gastric malignancy. Patients w/ difficulty in swallowing. Renal and hepatic impairment. Pregnancy and lactation. Lactation: Drug crosses into breast milk; discontinue drug, use caution

Side Effects

• 1-10% Headache (3%) <1% Abdominal pain
• Agitation
• Alopecia
• Confusion
• Constipation
• Diarrhea
• Dizziness
• Hypersensitivity reaction
• Nausea
• Vomiting Frequency Not Defined Anemia
• Necrotizing enterocolitis in fetus or newborn
• Pancreatitis (rare)
• Thrombocytopenia (rare)
• Pancytopenia (rare)
• Agranulocytosis (rare)
• Acquired immune hemolytic anemia (rare)
• Arthralgia (rare)
• Myalgia (rare) Potentially Fatal: Anaphylaxis
• hypersensitivity reactions.

Contra indication

Porphyria.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.